Staar Surgical CO DEF 14A proxy statements

STAAR Surgical Company has released its proxy statement for the 2026 Annual Meeting of Shareholders, detailing director nominations, equity plan amendments, auditor ratification, and executive compensation.

STAAR Surgical Company has adjourned its Special Meeting of Stockholders to January 6, 2026, at Alcon's request, in connection with their merger agreement.

STAAR Surgical Company urges stockholders to vote for the Alcon merger, highlighting the $30.75 per share cash offer and refuting Broadwood Partners' claims.

STAAR Surgical Company reports independent industry analysts and ISS recommend stockholders vote FOR the amended Alcon merger agreement at an increased price of $30.75 per share.

STAAR Surgical Company urges stockholders to vote for its amended merger agreement with Alcon, following a revised recommendation from Institutional Shareholder Services (ISS).

STAAR Surgical refutes activist investor allegations regarding its go-shop process and urges stockholders to accept Alcon's increased all-cash offer of $30.75 per share.

STAAR Surgical Company's merger agreement with Alcon has been amended, increasing the cash consideration for stockholders to $30.75 per share, up from $28.00, ahead of a crucial shareholder vote.

STAAR Surgical Company and Alcon Inc. announced an amendment to their merger agreement, increasing the cash consideration for STAAR shares to $30.75 per share.

STAAR Surgical Company announced an amendment to its merger agreement with Alcon, increasing the cash consideration for shareholders to $30.75 per share.

STAAR Surgical Company announced the expiration of its go-shop period for the Alcon merger, confirming no competing acquisition proposals were received.

STAAR Surgical Company has supplemented its proxy statement, announcing an amendment to its merger agreement with Alcon Research, LLC, introducing a 30-day go-shop period and eliminating termination fees under certain conditions.

STAAR Surgical Company has amended its merger agreement with Alcon, introducing a 30-day go-shop period and eliminating termination fees for superior offers from qualified bidders.

STAAR Surgical Company has postponed its special meeting to vote on the proposed $28.00 per share cash merger with Alcon Research, LLC until December 3, 2025, amidst significant shareholder opposition.

STAAR Surgical Company announced the postponement of its Special Meeting for the Alcon merger vote to December 3, 2025, citing ongoing discussions.

STAAR Surgical Company has postponed its special meeting of stockholders to vote on the Alcon merger agreement until December 3, 2025, citing ongoing discussions.

STAAR Surgical Company and Alcon Research, LLC have agreed to adjourn the special meeting of stockholders to vote on their proposed merger until November 6, 2025.

STAAR Surgical Company announced preliminary net sales of $94.7 million for Q3 2025, a 6.9% increase year-over-year, driven by a significant China shipment payment and growth outside China, despite reduced new orders from Chinese distributors.

STAAR Surgical Company reiterates that it has received no acquisition proposals other than from Alcon, refuting claims by Broadwood Partners ahead of a crucial stockholder vote.

STAAR Surgical's Board reiterates its unanimous recommendation for stockholders to approve the Alcon merger, disagreeing with a Glass Lewis report and highlighting a 59% premium.

STAAR Surgical highlights independent industry analyst support for its merger with Alcon, emphasizing the premium cash value and significant downside risks if the deal fails.

STAAR Surgical Company issued a statement refuting Broadwood Partners' claims, urging stockholders to vote for the Alcon merger, citing a significant premium and challenging business headwinds.

Alcon and STAAR Surgical announced the expiration of the Hart-Scott-Rodino waiting period, advancing Alcon's $1.5 billion acquisition of STAAR.

STAAR Surgical's Board unanimously recommends the $28.00 per share all-cash merger with Alcon, citing compelling premium and significant standalone risks.

Broadwood Partners, STAAR Surgical's largest shareholder, is soliciting proxies to vote against the proposed $28 per share acquisition by Alcon, citing undervaluation and a flawed sale process.

STAAR Surgical Company announced the expiration of its 45-day window shop period without receiving any competing acquisition proposals, reinforcing its board's determination that the Alcon merger maximizes stockholder value.

STAAR Surgical Company is urging shareholders to vote 'FOR' the proposed merger with Alcon, offering a compelling $28.00 per share cash value, ahead of the October 23, 2025 special meeting.

STAAR Surgical's Board of Directors unanimously recommends stockholders vote for the $28.00 per share cash merger with Alcon, citing significant premium and standalone challenges.

STAAR Surgical Company's Board unanimously recommends stockholders vote for the proposed $28.00 per share cash acquisition by Alcon.

STAAR Surgical Company's Board unanimously recommends stockholders approve a $28.00 per share all-cash merger with Alcon, representing a significant premium.

STAAR Surgical's CEO provided employees with an update on the Alcon acquisition, detailing compensation, benefits, and equity award treatment post-merger.